Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea
September 06 2024 - 12:15AM
UK Regulatory
Strong Cresemba® (isavuconazole) sales performance in Europe
triggers USD 25 million sales milestone payment to
Basilea
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, September 6, 2024
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a
commercial-stage biopharmaceutical company committed to meeting the
needs of patients with severe bacterial and fungal infections,
announced today that sales of the antifungal Cresemba®
(isavuconazole) by its license partner Pfizer in Europe exceeded
the threshold that triggered a milestone payment of
USD 25 million to Basilea.
David Veitch, Chief Executive Officer of Basilea, said: “We are
very pleased with the continued recognition of Cresemba in meeting
the critical medical needs of patients with life-threatening
invasive mold infections, and its strong sales performance in
Europe, which has resulted in this milestone payment. We already
announced several sales milestone payments from sales in Asia
Pacific and China this year. The number of sales milestone payments
triggered this year reflect Cresemba’s ongoing success and
sustained growth around the world.”
The license agreement between Basilea and Pfizer for Cresemba
covers Europe (excluding the Nordic countries) as well as 16
countries in the Asia Pacific region and China.
Cresemba is approved and marketed in more than 70 countries,
including the United States, most EU member states and additional
countries inside and outside of Europe. According to the latest
available market data, total global in-market sales of Cresemba
amounted to USD 489 million in the 12 months between
April 2023 and March 2024, a 24 percent growth
year-on-year.1
About isavuconazole
(Cresemba®)
Isavuconazole is an intravenous (i.v.) and oral azole
antifungal, commercialized under the trade name
Cresemba®. Basilea has entered into several license and
distribution agreements for isavuconazole covering approximately
115 countries. In the 27 European Union member states, as well
as in Iceland, Liechtenstein and Norway, isavuconazole is approved
for patients aged from 1 year of age and older for the treatment of
invasive aspergillosis and for the treatment of mucormycosis in
patients for whom amphotericin B is inappropriate.2
Isavuconazole is also approved in the United States (US) and
several additional countries in Europe and beyond, including the
U.K., China and Japan.3 It has orphan drug designation
in the US, Europe and Australia for its approved indications.
About Basilea
Basilea is a commercial-stage biopharmaceutical company founded
in 2000 and headquartered in Switzerland. We are committed to
discovering, developing and commercializing innovative drugs to
meet the needs of patients with severe bacterial and fungal
infections. We have successfully launched two hospital brands,
Cresemba for the treatment of invasive fungal infections and
Zevtera for the treatment of bacterial infections. In addition, we
have preclinical and clinical anti-infective assets in our
portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN).
Please visit basilea.com.
Disclaimer
This communication expressly or implicitly contains certain
forward-looking statements, such as "believe", "assume", "expect",
"forecast", "project", "may", "could", "might", "will" or similar
expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its
business, including with respect to the progress, timing and
completion of research, development and clinical studies for
product candidates. Such statements involve certain known and
unknown risks, uncertainties and other factors, which could cause
the actual results, financial condition, performance or
achievements of Basilea Pharmaceutica Ltd, Allschwil to be
materially different from any future results, performance or
achievements expressed or implied by such forward-looking
statements. Basilea Pharmaceutica Ltd, Allschwil is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.
For further information, please contact:
Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations
Basilea Pharmaceutica International Ltd, Allschwil
Hegenheimermattweg 167b
4123 Allschwil
Switzerland |
Phone |
+41 61 606 1102 |
E-mail |
media_relations@basilea.com
investor_relations@basilea.com |
This ad hoc announcement can be downloaded from
www.basilea.com.
References
- IQVIA Analytics Link, March 2024. In-market sales reported as
moving annual total (MAT) in US dollar.
- European Public Assessment Report (EPAR) Cresemba, not yet
updated to reflect recent extension to pediatric patients:
https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba [Accessed:
September 6, 2024]
- The registration status and approved indications may vary from
country to country.
Basilea Pharmaceutica (LSE:0QNA)
Historical Stock Chart
From Nov 2024 to Dec 2024
Basilea Pharmaceutica (LSE:0QNA)
Historical Stock Chart
From Dec 2023 to Dec 2024